Blue Trust Inc. Acquires 298 Shares of argenx SE (NASDAQ:ARGX)

Blue Trust Inc. increased its stake in argenx SE (NASDAQ:ARGX) by 413.9% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 370 shares of the company’s stock after purchasing an additional 298 shares during the quarter. Blue Trust Inc.’s holdings in argenx were worth $201,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. J.Safra Asset Management Corp increased its stake in argenx by 590.0% in the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock valued at $30,000 after purchasing an additional 59 shares in the last quarter. GAMMA Investing LLC increased its position in argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after buying an additional 40 shares in the last quarter. Point72 Hong Kong Ltd acquired a new position in argenx during the 2nd quarter worth approximately $76,000. Toronto Dominion Bank raised its stake in argenx by 16.5% during the 1st quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock worth $119,000 after buying an additional 43 shares during the period. Finally, Raymond James Trust N.A. bought a new position in argenx in the second quarter worth approximately $201,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Ratings Changes

ARGX has been the subject of several recent research reports. Wells Fargo & Company boosted their price objective on argenx from $543.00 to $547.00 and gave the company an “overweight” rating in a report on Friday, July 26th. JPMorgan Chase & Co. upped their price objective on shares of argenx from $500.00 to $640.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Oppenheimer upgraded shares of argenx from a “market perform” rating to an “outperform” rating and set a $546.00 price objective for the company in a report on Tuesday, July 23rd. Robert W. Baird boosted their target price on shares of argenx from $490.00 to $515.00 and gave the stock an “outperform” rating in a research report on Monday, July 29th. Finally, Deutsche Bank Aktiengesellschaft cut shares of argenx from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $550.44.

argenx Price Performance

Shares of argenx stock opened at $556.83 on Friday. The firm has a market cap of $33.09 billion, a PE ratio of -98.38 and a beta of 0.63. argenx SE has a 1 year low of $327.73 and a 1 year high of $571.97. The stock has a fifty day moving average price of $534.84 and a 200-day moving average price of $459.29.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $1.34. The business had revenue of $489.43 million during the quarter, compared to the consensus estimate of $436.66 million. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. During the same quarter last year, the company posted ($1.69) earnings per share. As a group, equities analysts anticipate that argenx SE will post -0.37 EPS for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.